Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 3467

Sort by

Sort Order Select

Journal Articles

ETNK1 Mutations in Atypical Chronic Myeloid Leukemia Induce a Mutator Phenotype That Can be Reverted with Phosphoethanolamine

Blood (2020) 136 (Supplement_2): LBA-5.

https://doi.org/10.1182/blood-2020-143852

Published: 2020

Journal Articles

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Blood (2020) 136 (Supplement_2): LBA-4.

https://doi.org/10.1182/blood-2020-143816

Published: 2020

Journal Articles

RASA3 Regulates Stage-Specific AKT Signaling and Cell Cycle Progression in Mammalian Erythropoiesis

Elena C. Brindley, BS, Emily Hartman, BS, Julien Papoin, MS, Jeffrey Michael Lipton, MDPhD, Luanne L. Peters, PhD, Lionel Blanc, PhD

Blood (2020) 136 (Supplement 1): 3.

https://doi.org/10.1182/blood-2020-139425

Published: 2020

Journal Articles

A Phase I Study of Lintuzumab Ac225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML

Sameem Abedin, MD, Guru Subramanian Guru Guru Murthy, MBBS, Mehdi Hamadani, MD, Laura C. Michaelis, MD, Lyndsey Runaas, MD, Karen-Sue Carlson, MDPhD, Alexandra M. Harrington, MDMT(ASCP), Ehab L. Atallah, MD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-137218

Published: 2020

Journal Articles

Not All Patients Benefit from Switching to Ehl: Results from the Wapps Database

Olav Versloot, MSc, Emma Iserman, Pierre Chelle, PhD, Federico Germini, MD MSc, Tushara Mathew, Alfonso Iorio, MDPhD, Kathelijn Fischer

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-142816

Published: 2020

Journal Articles

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2020) 136 (Supplement 1): 11–13.

https://doi.org/10.1182/blood-2020-139903

Published: 2020

Journal Articles

Terminal Half-Life of Factor VIII/IX According to Age and Blood Group Based on 8550 Assessments

Olav Versloot, MSc, Emma Iserman, Pierre Chelle, PhD, Federico Germini, MD MSc, Tushara Mathew, Alfonso Iorio, MDPhD, Kathelijn Fischer

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-141801

Published: 2020

Journal Articles

Conversion from MRD Positive to Negative Status in AML Patients in CR1 after Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Arjan van de Loosdrecht, MD PhD, Janine van Elssen, MDPhD, Bjørn Tore Gjertsen, Eva Maria Wagner, MD, Tobias Holderried, MD, Uwe Platzbecker, Jacqueline J Cloos, Jeroen Rovers, MD PhD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-139266

Published: 2020

Journal Articles

Hottip -Mediated R-Loops Regulate CTCF TAD Boundary to Control WNT/b-Catenin Pathway in AML Genome

Huacheng Luo, PhD, Ganqian Zhu, PhD, Xiaoyan Ma, MD PhD, David F. Claxton, MD, Yi Qiu, PhD, Mingjiang Xu, MDPhD, Suming Huang, PhD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-137816

Published: 2020

Journal Articles

Global Treatment Satisfaction Levels and Treatment Patterns from the International Sickle Cell World Assessment Survey (SWAY): Hydroxyurea (HU) Versus No HU

Blood (2020) 136 (Supplement 1): 8–10.

https://doi.org/10.1182/blood-2020-137103

Published: 2020

Journal Articles

Phase I Studies in Hematologic Malignancy: 20-Year Experience from Cancer Therapy Evaluation Program (CTEP) at National Cancer Institute/National Institutes of Health

Dai Chihara, MDPhD, Erich P. Huang, PhD, Shanda R. Finnigan, MPH, RN, Lisa M. Cordes, PharmD, Nebojsa Skorupan, MD, Yoko Korenaga Fukuda, MD, Larry V. Rubinstein, PhD, Naoko Takebe, MD PhD

Blood (2020) 136 (Supplement 1): 18.

https://doi.org/10.1182/blood-2020-140159

Published: 2020

Journal Articles

Thrombotic Microangiopathy Variants Are Independently Associated with Critical Disease in COVID-19 Patients

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-139304

Published: 2020

Journal Articles

In Situ Vaccination in Lymphoma Using Photothermal Therapy with CpG Deoxynucleotide Coated Branched Gold Nanoparticles: Analysis of Tumor Growth and Immune Response in a Murine Xenograft Model

Adam Yuh Lin, MDPhD, Bongseo Choi, PhD, Taehoon Sim, PhD, Leo I. Gordon, MD, Dong-Hyun Kim, PhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-141589

Published: 2020

Journal Articles

Paired Single Cell RNA and TCR Sequencing Analysis Following PD-L1 Blockade in Cutaneous T-Cell Lymphoma

Christiane Querfeld, MDPhD, Xiwei Wu, PhD, Hanjun Qin, PhD, Chingyu Su, Zhen Han, Steven T. Rosen, MD

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-139992

Published: 2020

Journal Articles

Co-Targeting BET Bromodomain Proteins and Aberrant Signaling in AML

Benjamin J. Huang, MD, Xinyue Wang, BA, Max Harris, BA, Anica Wandler, PhD, Eugene Hwang, BA, Michael R. Burgess, MD PhD, Qing Li, MD PhD, Paul Severson, PhD, Ben Powell, PhD, Edward A. Kolb, MD, Soheil Meshinchi, MDPhD, Barry S Taylor, PhD, Gideon Bollag, PhD, Kevin M. Shannon, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-142921

Published: 2020

Journal Articles

Impact of Sars-CoV2 Infection on 491 Hematological Patients: The Ecovidehe Multicenter Study

Cristina De Ramón, Jose Angel Hernandez-Rivas, MD PhD, Jose Antonio Rodríguez García, Enrique M. Ocio, MDPhD, María Teresa Gómez-Casares, MD PhD, Javier López Jiménez, MD PhD, Carlos Solano, MD PhD, Joaquín Martínez-López, Anna Sureda, Manuel Jurado, MD PhD, Raul Córdoba, MD PhD, Celina Benavente, Pascual Marco, Jose Antonio Pérez-Simón, MD, Jose Maria Moraleda, MD PhD, Angela Figuera, Emilia Pardal, Cristina Pascual Izquierdo, PhD MD, Ramon Garcia-Sanz

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-142292

Published: 2020

Journal Articles

Outcomes of a Clinician-Directed Protocol for Discontinuation of Complement Inhibition Therapy in Atypical Hemolytic Uremic Syndrome

Noor Dhaliwal, Sarah Hussain, Harshvardhan Upreti, Evan M Braunstein, MDPhD, Xuan Yuan, MD MSc, Alison R. Moliterno, MD, Robert Brodsky, MD, Shruti Chaturvedi, MBBS,MS

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-142965

Published: 2020

Journal Articles

LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenström's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study

Blood (2020) 136 (Supplement 1): 8–10.

https://doi.org/10.1182/blood-2020-134314

Published: 2020

Journal Articles

SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia

Stephane De Botton, Thomas Cluzeau, MDPhD, Carlos Enrique Vigil, MD, Rachel J. Cook, MD, Philippe Rousselot, MDPhD, David A Rizzieri, MD, Jane L. Liesveld, MD, Pierre Fenaux, MD PhD, Thorsten Braun, MD PhD, Anne Banos, MD, Michael R. Savona, MD, Don Park, MD, Michael J. Kelly, MD MPH, MS, Angela Volkert, Li Zhou, PhD, Qing Kang-Fortner, PhD, David A. Roth, MD, Eytan M. Stein, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-134600

Published: 2020

Journal Articles

Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

Eytan M. Stein, MD, Stephane De Botton, Thomas Cluzeau, MDPhD, Arnaud Pigneux, MD PhD, Jane L. Liesveld, MD, Rachel J. Cook, MD, Philippe Rousselot, MDPhD, David A Rizzieri, MD, Thorsten Braun, MD PhD, Dale L. Bixby, MD, Gail J. Roboz, MD, Delphine Lebon, MD, Mael Heiblig, Michael J. Kelly, MD MPH, MS, Angela Volkert, Li Zhou, PhD, Qing Kang-Fortner, PhD, David A. Roth, MD, Pierre Peterlin, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-134602

Published: 2020

NARROW

ETNK1 Mutations in Atypical Chronic Myeloid Leukemia Induce a Mutator Phenotype That Can be Reverted with Phosphoethanolamine

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

RASA3 Regulates Stage-Specific AKT Signaling and Cell Cycle Progression in Mammalian Erythropoiesis

A Phase I Study of Lintuzumab Ac225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML

Not All Patients Benefit from Switching to Ehl: Results from the Wapps Database

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Terminal Half-Life of Factor VIII/IX According to Age and Blood Group Based on 8550 Assessments

Conversion from MRD Positive to Negative Status in AML Patients in CR1 after Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Hottip -Mediated R-Loops Regulate CTCF TAD Boundary to Control WNT/b-Catenin Pathway in AML Genome

Global Treatment Satisfaction Levels and Treatment Patterns from the International Sickle Cell World Assessment Survey (SWAY): Hydroxyurea (HU) Versus No HU

Phase I Studies in Hematologic Malignancy: 20-Year Experience from Cancer Therapy Evaluation Program (CTEP) at National Cancer Institute/National Institutes of Health

Thrombotic Microangiopathy Variants Are Independently Associated with Critical Disease in COVID-19 Patients

In Situ Vaccination in Lymphoma Using Photothermal Therapy with CpG Deoxynucleotide Coated Branched Gold Nanoparticles: Analysis of Tumor Growth and Immune Response in a Murine Xenograft Model

Paired Single Cell RNA and TCR Sequencing Analysis Following PD-L1 Blockade in Cutaneous T-Cell Lymphoma

Co-Targeting BET Bromodomain Proteins and Aberrant Signaling in AML

Impact of Sars-CoV2 Infection on 491 Hematological Patients: The Ecovidehe Multicenter Study

Outcomes of a Clinician-Directed Protocol for Discontinuation of Complement Inhibition Therapy in Atypical Hemolytic Uremic Syndrome

LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenström's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study

SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia

Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only